BCMA CAR-T for Dynamic High-risk Multiple Myeloma

This is a single-arm, open-label study to evaluate the efficacy and safety of BCMA CAR-T in dynamic high-risk patients with multiple myeloma

Trial Details

NCT ID
NCT06880393
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • anti-BCMA-CAR-T
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Be informed and voluntarily sign the Informed Consent Form (ICF).
  • Age between 18 and 75 years (inclusive).
  • Have measurable disease meeting at least one of the following criteria: Serum M-protein ≥1 g/dL (\>10 g/L) as detected by serum protein electrophor…
  • Have received only one line of standard anti-myeloma therapy, including: Induction therapy with at least one proteasome inhibitor, one immunomodula…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →